CRISPR Gene Therapy Exa-cel Frees Young Children from Sickle Cell and Thalassemia
Phase 3 data show exa-cel eliminated transfusions and vaso-occlusive crises in children ages 5–11 with serious inherited blood disorders.
Summary
Exagamglogene autotemcel (exa-cel), a CRISPR-based gene therapy, was tested in children aged 5 to 11 with transfusion-dependent β-thalassemia or sickle cell disease — conditions that normally require lifelong blood transfusions or cause repeated painful crises. The therapy edits patients' own blood stem cells to reactivate fetal hemoglobin production. In this early pediatric extension of larger trials, all 8 evaluable thalassemia patients achieved transfusion independence and all 8 evaluable sickle cell patients remained free of severe vaso-occlusive crises at 16 months of follow-up. While results are promising, all children experienced serious adverse events, and one child died from a conditioning-related liver complication. The findings support exa-cel's potential as a one-time curative therapy for young children with these devastating diseases.
Detailed Summary
Inherited blood disorders like sickle cell disease and transfusion-dependent β-thalassemia impose enormous burdens on children and families — requiring lifelong blood transfusions, causing recurrent painful crises, and shortening life expectancy. Gene therapy offers the possibility of a one-time cure by correcting the underlying genetic defect rather than managing symptoms indefinitely.
This study reports pediatric data from two ongoing phase 3 trials (CLIMB THAL-141 and CLIMB SCD-151) evaluating exa-cel in children aged 5 to 11. Exa-cel works by harvesting a patient's own CD34+ hematopoietic stem cells, using CRISPR-Cas9 to edit the BCL11A erythroid enhancer region, then reinfusing the modified cells after myeloablative conditioning with busulfan. This edit reactivates fetal hemoglobin, which compensates for the dysfunctional adult hemoglobin in both diseases.
Fifteen children with thalassemia and 11 with sickle cell disease received exa-cel. With median follow-up of approximately 16–17 months, all 8 evaluable thalassemia patients achieved transfusion independence for at least 12 consecutive months, and all 8 evaluable sickle cell patients remained free of severe vaso-occlusive crises. The remaining patients had not yet reached the 16-month evaluation window.
However, the safety profile warrants careful attention. Every child experienced at least one grade 3 or 4 adverse event. Two thalassemia patients developed severe veno-occlusive liver disease attributed to busulfan conditioning, and one of these children died. This underscores that myeloablative conditioning — not the gene editing itself — carries significant risk, particularly in younger patients.
These results extend the efficacy seen in older adolescents and young adults to a younger age group, suggesting exa-cel may eventually be deployed earlier in disease course. However, long-term durability data and strategies to reduce conditioning toxicity remain critical unanswered questions before this therapy can be considered standard of care for young children.
Key Findings
- 8 of 8 evaluable thalassemia children achieved transfusion independence for at least 12 months after exa-cel.
- 8 of 8 evaluable sickle cell children remained free of severe vaso-occlusive crises at 16-month follow-up.
- All 26 children experienced at least one grade 3 or 4 adverse event post-treatment.
- One child with thalassemia died from severe busulfan-related veno-occlusive liver disease.
- Results extend exa-cel's efficacy profile down to children as young as 5 years old.
Methodology
Two ongoing phase 3, open-label, single-group studies enrolled children aged 5–11 with transfusion-dependent β-thalassemia (n=15) or sickle cell disease (n=11). Participants received myeloablative busulfan conditioning with pharmacokinetic dose adjustment before exa-cel infusion. Primary endpoints were transfusion independence or freedom from severe vaso-occlusive crises for at least 12 consecutive months.
Study Limitations
The study is limited by small sample sizes (15 thalassemia, 11 sickle cell) and short median follow-up of approximately 16–17 months, leaving long-term durability unknown. Many patients had not yet reached the primary endpoint evaluation window, making efficacy conclusions preliminary. This summary is based on the abstract only, as the full text is not open access; complete safety data, engraftment kinetics, and subgroup analyses are not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.